Cystic fibrosis biotech Nivalis Therapeutics sets terms for $60 million IPO - (NASDAQ via NewsPoints Desk)

  • Nivalis Therapeutics disclosed in a regulatory filing plans to raise up to $60 million in an initial public offering (IPO), as reported NASDAQ Wednesday.
  • In the IPO, the drugmaker, which is developing an experimental treatment for cystic fibrosis, will offer 4.3 million shares at a per-share price of $13 to $15.
  • At the midpoint of the proposed range, Nivalis would have a market capitalisation of $200 million.

To read more NewsPoints articles, click here.